The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...
Cost-Benefit Analysis, Tuberculosis, Multidrug-Resistant/drug therapy, Drug Therapy, Combination, Nitroimidazoles/therapeutic use, Treatment Outcome, Antitubercular Agents/therapeutic use, Tuberculosis, Pulmonary/drug therapy, Clinical Trials as Topic, Nitroimidazoles/economics, Antitubercular Agents/economics